Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
From the U.S. FDA-approved label for Metoprolol. Full label: DailyMed.
Metoprolol tartrate tablets are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Angina Pectoris. Myocardial Infarction, to reduce the risk of cardiovascular mortality when used in conjunction with intravenous metoprolol therapy in patients with definite or suspected acute myocardial infarction in hemodynamically stable patients.
From the U.S. FDA-approved label for Metoprolol. Full label: DailyMed.
Administer once daily with food or after a meal. Titrate at weekly or longer intervals as needed and tolerated. Hypertension: Recommended starting dosage is 100 mg daily, in single or divided doses.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Metoprolol tartrate tablets are contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, systolic blood pressure <100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product. Known hypersensitivity to product components. Severe bradycardia: Greater than first degree heart block, or sick sinus syndrome without a pacemaker. Cardiogenic shock or decompensated heart failure.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Abrupt cessation may exacerbate myocardial ischemia. Heart Failure: Worsening cardiac failure may occur. Bronchospastic Disease: Avoid beta-blockers. Pheochromocytoma: Initiate therapy with an alpha blocker. Major Surgery: Avoid initiation of high-dose extended-release metoprolol in patients undergoing non-cardiac surgery. Do not routinely withdraw chronic beta-blocker therapy prior to surgery. Diabetes: May mask symptoms of hypoglycemia. Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. Peripheral Vascular Disease: Can aggravate symptoms of arterial insufficiency.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse reactions are described elsewhere in labeling: Worsening angina or myocardial infarction Worsening heart failure. Worsening AV block. Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
Store at 20° to 25 °C (68° to 77 °F); Protect from moisture and heat.
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
